Since ATL1102 returned impressive results in a phase II trial in non-ambulant Duchenne muscular dystrophy (naDMD) patients, Antisense Therapeutics (ASX: ANP) has been perfecting its regulatory strategy for the compound. The next naDMD trial, if positive, will be central to a Marketing Authorisation Application to the European Medicines Agency for naDMD patients. Antisense’s US strategy provides several options and leverages its European Union activities leading to a New Drug Application to the US Food and Drug Administration for naDMD. Now, it comes down to execution.
Corporate Connect analyst Marc Sinatra has released an updated comprehensive research report on ANP, placing a 12-month target on the company of $0.55 per share. Visit ANP’s company page to download this report.
Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development.